Skip Navigation

European Heart Journal 1998 19(11):1712-1718; doi:10.1053/euhj.1998.1126
Copyright © 1998 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Poldermans, D.
Right arrow Articles by Roelandt, J.R.T.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poldermans, D.
Right arrow Articles by Roelandt, J.R.T.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction

D. Poldermansaf1, R. Rambaldia, J.J. Baxa, J.H. Cornela, I.R. Thomsonb, R. Valkemaa, E. Boersmaa, P.M. Fiorettia, C.S.M. Breburdaa and J.R.T.C. Roelandta

a Erasmus University, Rotterdam, the Netherlands
b University of Manitoba, Winnipeg, Manitoba, Canada

accepted May 6, 1998

Objective

To assess the feasibility safety and side effects of the addition of atropine to dobutamine stress echocardio-graphy for the detection of viable myocardium in patients with left ventricular dysfunction (ejection fraction ≤35%) prior to coronary revascularization.

Background

The assessment of viable and/or ischaemic myocardium has high prognostic value as regards improvement of function and survival after coronary revasculariz-ation. The addition of atropine to dobutamine during echocardiographic testing for the presence of viable myocardium is not common practice. Consequently, no data exist on the safety and additional diagnostic value of this practice.

Methods

Two hundred patients with left ventricular ejection fraction ≤35% were studied.

Results

Test end-points were: target heart rate in 164 (82%) of the patients, severe angina in 18 (9%), maximum dobutamine–atropine dose in six (3%), severe ST segment changes in five (2%), cardiac arrhythmias in four (2%), and hypotension in three (1%). Viability could be assessed echocardiogaphically in 105/200 (53%) from a biphasic response (improvement of wall motion with low dose dobutamine and worsening with high dose), in 93 from ischaemia and in 12 from sustained or late improvements. In 36/105 (34%) patients, ischaemic myocardium could only be assessed after the addition of atropine. Cardiac arrhythmias occurred in 11/200 (6%) and hypotension (decrease of systolic blood pressure >30mmHg) in 21/200 (11%). Neither the use of atropine nor the induction of ischaemia were associated with an increased incidence of cardiac arrhythmias or hypotension.

Conclusions

In a large group of patients with severe left ventricular dysfunction, dobutamine stress echocardiography is feasible and safe in 186/200 (93%); the addition of atropine was necessary in 34% to assess myocardial viability. Hypotension and cardiac arrhythmias were the most frequent side effects, but were not related to the induction of ischaemia or addition of atropine.The European Society of Cardiology

Key Words: Dobutamine stress echocardiography • atropine addition • poor left ventricular function

f1 Correspondence: Don Poldermans, MD, PhD, Thoraxcentre, Room Ba 300, Erasmus University, Rotterdam, The Netherlands.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EchocardiogrHome page
P. S. Sethi, W. Hiser, H. Gaffar, L. Jiang, A. Islam, N. Bhatnagar, and M. Slawsky
Fatal pheochromocytoma crisis precipitated by dobutamine stress echocardiography
Eur J Echocardiogr, June 13, 2008; (2008) jen180v1.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M D Kertai, E Boersma, J J Bax, M H Heijenbrok-Kal, M G M Hunink, G J L'talien, J R T C Roelandt, H van Urk, and D Poldermans
A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery
Heart, November 1, 2003; 89(11): 1327 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T Zaglavara, R Haaverstad, B Cumberledge, T Irvine, H Karvounis, G Parharidis, G Louridas, and A Kenny
Dobutamine stress echocardiography for the detection of myocardial viability in patients with left ventricular dysfunction taking {beta} blockers: accuracy and optimal dose
Heart, April 1, 2002; 87(4): 329 - 335.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. J. Bax, D. Poldermans, A. Elhendy, J. H. Cornel, E. Boersma, R. Rambaldi, J. R. T. C. Roelandt, and P. M. Fioretti
Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography
J. Am. Coll. Cardiol., July 1, 1999; 34(1): 163 - 169.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.